pharma · HIV-1 Infection · HIV-1 infection
Gilead Sciences
Gilead Sciences Pty Limited
Gilead Sciences clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 30
- Drugs
- 54
- Patents
- 0
Gilead Sciences projects
3 ClinicalTrials.gov programs sponsored by Gilead Sciences.
Gilead Sciences has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
GS-5245 tablets 175 mg, GS-5245 tablets 350 mg
Gilead Sciences Pty Limited
Renal Impairment
1 trial -
Study of GS-0151 in Participants With Rheumatoid Arthritis
Gilead Sciences Pty Limited
Rheumatoid Arthritis
1 trial -
Study of GS-5319 in Adults With Solid Tumors
Gilead Sciences Pty Limited
Advanced solid tumors
1 trial
Frequently asked questions
How many clinical projects does Gilead Sciences have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.